Light Blue Pterodactylus Cufflinks - New Release
We’d prefer if you didn’t squawk loudly while wearing these. It would reflect on us. But, these are light-hearted yet just this side of demure. Perfect for occasions that don’t even know they’re occasions. Approximately 1 1/8" x 3/8", Silver plated and enamel, Bullet back closure,
The International Maritime Organisation (IMO) is introducing new rules on marine fuels from 2020, limiting the sulphur content to 0.5 percent, from 3.5 percent currently, to curb pollution produced by the world’s ships. The shipping and oil refining industries are scrambling to prepare for the shift and have made large investments to comply with the new standards since they were announced in 2016. Exxon’s Singapore refinery is the company’s largest, with a capacity of about 592,000 barrels a day. Singapore is also home to the oil giant’s biggest integrated petrochemical complex.
ZURICH (Reuters) light blue pterodactylus cufflinks - Swiss drugmaker Roche (ROG.S) is breaking into hemophilia A treatment, a $10 billion global market dominated by rivals who have cultivated close ties to sufferers of the genetic bleeding disorder, Roche’s Hemlibra, on sale since late 2017 for patients with resistance to existing treatments, is widely expected to win the U.S, Food and Drug Administration’s blessing for use in nearly all patients this week, The FDA declined to comment, First-half sales were just 57 million Swiss francs ($58 million)..
To hit $5 billion global annual sales that some analysts forecast, Hemlibra must wrest business away from hemophilia giants like Shire SHP.L, Bayer (BAYGn.DE), Novo Nordisk (NOVOb.CO) and Octapharma, whose “clotting factors” are now standard for people who lack proteins that stop bleeding. These companies have long sponsored patient groups, summer camps, even kayak trips on the Pacific Ocean, as part of efforts to build loyalty they hope will slow an exodus from their products once new drugs like Roche’s arrive.
Roche is convinced word of mouth in the hemophilia community, backed up by its studies showing that Hemlibra shots may be more effective and must be administered less frequently than infusions of clotting factors, will overcome any current allegiances, “I’m not familiar with what the other companies are telling the patients,” said Dr, Gallia Levy, who heads Roche’s Hemlibra program, “What I do know is that I’ve seen a lot of patients telling other patients what is happening in their lives, Those sorts of stories mean the light blue pterodactylus cufflinks most to the patients.”..
As part of Roche’s initial marketing campaign for Hemlibra, it has produced videos of hemophilia patients participating in daily activities, including riding bikes, in spite of their serious illness. One video shows the consequences of failing to get appropriate treatment, featuring a Serbian man who suffered joint bleeds as a child and now must use crutches. Hemophilia A has become one of medicine’s most lucrative diseases, despite just 20,000 patients in the United States and several hundred thousand worldwide. It almost always affects men, passed down by a mutation on the X chromosome from their mother.
In 2016, the U.S, government alone spent some $2 billion on hemophilia A therapies, data from its Medicaid and Medicare insurance programs show, Shire’s Adynovate clotting factor runs at $537,000 annually, although costs for severe light blue pterodactylus cufflinks patients can hit several million dollars, Roche has priced Hemlibra at $482,000, hefty but a level the independent U.S, pricing group ICER has said could cut overall hemophilia treatment costs significantly, Traditionally a cancer drugs maker, Roche is turning to rare diseases like hemophilia to replace revenue from its older medicines whose expiring patents have exposed the company to unprecedented generic competition..
Hemophilia represents the largest market for rare diseases and is expected to grow above 7 percent per year through 2022, Evaluate Pharma has forecast. In August, Roche defeated a challenge from Shire aimed at delaying Hemlibra’s broad introduction. Shire fears losing 30 percent of its $2.4 billion annual clotting factors sales to Hemlibra in the short term, court documents show. However, it also indicated it expected patient allegiances to at least mitigate losses. “Patients have loyalty to the brand and to manufacturers, and physicians are reluctant to switch due to risks,” according to Shire testimony cited in the U.S. federal court judge’s ruling.
Clotting-factor makers have fostered this loyalty, in part, by sponsoring summer camps for patients and their families, Camp Red Sunrise in Idaho’s Rocky Mountains, sponsored by Shire and Bayer, among others, is free, Another Shire-sponsored retreat, Missouri’s Camp Notaclotamongus, costs $25, In September, Switzerland-based Octapharma sponsored a free light blue pterodactylus cufflinks sea kayaking expedition for 10 hemophilia patients on Washington State’s Puget Sound, offering a chance to see pods of orca killer whales..